IRIS
RASI, GUIDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.228
EU - Europa 2.338
AS - Asia 704
Continente sconosciuto - Info sul continente non disponibili 10
SA - Sud America 8
AF - Africa 4
OC - Oceania 4
Totale 30.296
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.198
CN - Cina 516
UA - Ucraina 442
DE - Germania 345
IT - Italia 323
IE - Irlanda 294
PL - Polonia 283
FR - Francia 238
SE - Svezia 135
GB - Regno Unito 119
KR - Corea 101
FI - Finlandia 88
RU - Federazione Russa 43
CA - Canada 29
JP - Giappone 24
IN - India 15
HK - Hong Kong 9
UZ - Uzbekistan 9
BE - Belgio 8
EU - Europa 8
IL - Israele 7
SG - Singapore 5
AT - Austria 4
AU - Australia 4
BR - Brasile 4
VN - Vietnam 4
CL - Cile 3
IR - Iran 3
NL - Olanda 3
RO - Romania 3
TR - Turchia 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CH - Svizzera 2
ES - Italia 2
GR - Grecia 2
NG - Nigeria 2
SA - Arabia Saudita 2
DM - Dominica 1
EC - Ecuador 1
EG - Egitto 1
GH - Ghana 1
HU - Ungheria 1
ID - Indonesia 1
LK - Sri Lanka 1
LV - Lettonia 1
MY - Malesia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 30.296
Salva come PNG Salva come JPEG
Città #
Woodbridge 8.350
Wilmington 7.775
Houston 6.551
Ann Arbor 807
Fairfield 695
Jacksonville 414
Chandler 381
Ashburn 341
Dublin 292
Kraków 283
Seattle 265
Cambridge 248
Medford 242
Beijing 216
Dearborn 163
Lawrence 106
Rome 88
Zhengzhou 87
Hangzhou 77
Mülheim 70
New York 52
San Diego 48
Milan 34
Menlo Park 29
Falls Church 26
Toronto 24
Boardman 23
Shanghai 22
Hefei 19
University Park 19
Nanjing 18
San Mateo 18
London 16
Norwalk 16
Verona 16
Redwood City 13
Mountain View 11
Kunming 10
Fukuoka 9
Saint Petersburg 9
Bologna 8
Brussels 8
Chengdu 7
Nürnberg 7
Palo Alto 7
Detroit 6
Jinan 6
Seoul 6
Auburn Hills 5
Florence 5
Guangzhou 5
Marano Di Napoli 5
Nanchang 5
Redmond 5
Ridgeland 5
Chongqing 4
Hanoi 4
Indiana 4
Kilburn 4
Leawood 4
Naples 4
Shenyang 4
Vienna 4
Washington 4
Ahmedabad 3
Alghero 3
Baotou 3
Changsha 3
Chiswick 3
Helsinki 3
Hyderabad 3
Los Angeles 3
San Francisco 3
São Paulo 3
Tai Po Kau 3
Yangcheon-gu 3
Ypsilanti 3
Abuja 2
Acton 2
Aliminusa 2
Amsterdam 2
Augusta 2
Berlin 2
Camerino 2
Clearwater 2
Halifax 2
Lappeenranta 2
Lastra a Signa 2
Mapo-gu 2
Minturno 2
Ningbo 2
Origgio 2
Paris 2
Portici 2
Pune 2
Ravenna 2
Taipei 2
Turin 2
Abbotsford 1
Accra 1
Totale 28.092
Salva come PNG Salva come JPEG
Nome #
Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance 480
Thymosin alpha 1: From bench to bedside 470
Vaccination with a synthetic nonapeptide expressed in human tumors prevents colorectal cancer liver metastases in syngeneic rats 465
Transcription profile of human lymphocytes following in vitro treatment with thymosin alpha-1. 453
ANTITUMOR EFFECT OF COMBINED TREATMENT WITH THYMOSIN ALPHA-1 AND INTERLEUKIN-2 AFTER 5-FLUOROURACIL IN LIVER METASTASES FROM COLORECTAL-CANCER IN RATS 436
Anti-proliferative effect of atrial natriuretic peptide on colorectal cancer cells: evidence for an Akt-mediated cross-talk between NHE-1 activity and Wnt/β-catenin signaling 429
Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma 423
Thymosin alpha 1: from bench to bedside 418
TCTP is a critical survival factor that protects cancer cells from oxidative stress-induced cell-death. 417
Feasibilty of in utero DNA vaccination following naked gene transfer into pig fetal muscle: transgene expression, immunity and safety 416
Combination low-dose lymphoblastoid interferon and thymosin alpha(1) therapy in the treatment of chronic hepatitis B 415
Combined treatment with thymosin-alpha 1 and low dose interferon-alpha after dacarbazine in advanced melanoma 413
Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union 413
Combination therapy with BRMs in cancer and infectious diseases 410
Access to patient-level trial data--a boon to drug developers 407
Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer 406
Treatment of aspergillus infection with thymosin alpha 1 406
Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application 398
The risks of risk aversion in drug regulation 398
Drug policy for an aging population--the European Medicines Agency's geriatric medicines strategy 397
Detection of high levels of Survivin-immunoglobulin M immune complex in sera from hepatitis C virus infected patients with cirrhosis 397
Transcription profile of human lymphocytes following in vitro treatment with thymosin alpha-1 395
Differential expression of a new tumor-associated antigen, TLP, during human colorectal cancer tumorigenesis 393
Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma 387
Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. 384
Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer 379
Vaccination with a synthetic nonapeptide expressed in human tumors prevents colorectal cancer liver metastases in syngeneic rats 378
null 376
thymosin alpha1 activates the tlr9/myd88/irf7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo 376
Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies 376
Anti-tumour immunogens and vaccines 375
Combination low-dose lymphoblastoid interferon and thymosin α1 therapy in the treatment of chronic hepatitis B 370
High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma 368
Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma 367
Combination therapy with BRMs in cancer and infectious diseases 367
The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation 366
comparative cellular signal patway analysis of metastatic colorectal cancer in human and preclinical animal model 366
Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee 363
Evaluation of antigen specific recognition and cell mediated cytotoxicity by a modified lysispot assay in a rat colon carcinoma model 362
Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a 361
An audience with Guido Rasi. Interview by Asher Mullard 360
Combination thymosin alpha(1) and lymphoblastoid interferon treatment in chronic hepatitis C 358
ACTIVATION OF HUMAN ENDOGENOUS RETROVIRUS-K AND PRODUCTION OF INFECTIOUS VIRUS-LIKE PARTICLES IN HUMAN MELANOMA CELLS ABS -0153 354
Thymosin alpha 1 in combination with cytokines and chemotherapy for the treatment of cancer 351
Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional healthcare providers 351
differentiation therapy: in vitro evidence making cyanidin-3-o--glucopiranoside useful for prevention and treatment of melanoma 349
Straight talk with...Guido Rasi. Interview by Roxanne Khamsi 348
Microfabricated biocapsules provide short-term immunoisolation of insulinoma xenografts 346
Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice 346
Fifty years after thalidomide; what role for drug regulators? 346
null 342
nerve growth factor (ngf) and cirrhosis: a possible new marker of progression to hepatocellular carcinoma (hcc) 340
COMPARATIVE CELLULAR SIGNAL PATWAY ANALYSIS OF METASTATIC COLORECTAL CANCER IN HUMAN AND PRECLINICAL ANIMAL MODEL 340
up-regulation of melanocytic differentiation antigens induced by cyanidin-3-o--glucopyranoside in human melanoma cells. 339
Stimulatory effect of Eucalyptus essential oil on innate cell-mediated immune response 338
early detection of molecular markers suitable for colorectal cancer diagnosis and therapy in a carcinogenesis model 338
Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma 337
Method of up-regulating tumor antigen expression using thymalfasin 333
Preclinical studies using oncofidä-s, a new sn38-hyaluronic acid bioconyugate, for cd44-targeted therapy of colon carcinoma 331
Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. 330
Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application 324
up-regulation of melan-a/mart-1 antigen expression during human melanoma cell differentiation 322
Differentiation of human melanoma cells induced by cyanidin-3-O-beta-glucopyranoside 321
preventive peptide vaccine for colorectal cancer metastases 321
Thymosin alpha1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo 318
Survivin-Igm Immuno Complex: A Novel Candidate Biomarker Of Cirrhosis To Monitor Patients Progression Towards Hepatocellular Carcinoma 317
COMBINATION THERAPY WITH THYMOSIN ALPHA-1 POTENTIATES THE ANTITUMOR-ACTIVITY OF INTERLEUKIN-2 WITH CYCLOPHOSPHAMIDE IN THE TREATMENT OF THE LEWIS LUNG-CARCINOMA IN MICE 315
nerve growth factor (ngf): a possible marker for hepatocellular carcinoma (hcc)? 314
Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha 1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery 312
Characterization of four newly established melanoma cell lines 307
Cytoplasmic localization of anthracycline antitumor drugs conjugated with reduced glutathione: a possible correlation with multidrug resistance mechanisms 306
Influenza della concentrazione di adriamicina su modificazioni volumetriche e proliferazione di cellule leucemiche in vitro 301
Rationale for therapeutic approaches with thymic hormones, interleukin 2 and interferon in combination with chemotherapy. 290
WNT-pathway components as predictive markers useful for diagnosis, prevention and therapy in inflammatory bowel disease and sporadic colorectal cancer 279
Stimolazione in vivo mediante prostaglandine ed interferone dell'attività natural killer in topi trattati con ciclofosfamide. vol. 87, p. 595-603 278
Metformin induces apoptosis and downregulates pyruvate kinase M2 in breast cancer cells only when grown in nutrient-poor conditions 190
A new tumour associated antigen of non-small cell lung cancer: Tumour Liberated Proteins (TLP) - A possible new tumor marker 185
Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: A phase-II controlled trial 168
A new tumour associated antigen of non-small cell lung cancer: Tumour liberated proteins (TLP) - A possible new tumor marker 164
Sequential biochemotherapy for metastatic colorectal cancer using, fluorouracil, folinic acid, thymopentin and interleukin-2: Clinical and immunological effects 155
Open clinical trial data for all? A view from regulators 155
BIOCHEMOTHERAPY WITH THYMOSIN-ALPHA-1, INTERLEUKIN-2 AND DACARBAZINE IN PATIENTS WITH METASTATIC MELANOMA - CLINICAL AND IMMUNOLOGICAL EFFECTS 138
Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma 109
Clinical trial publications: A sufficient basis for healthcare decisions? 109
Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation 99
From adaptive licensing to adaptive pathways: Delivering a flexible life-span approach to bring new drugs to patients 99
How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice 85
Big Data – How to Realize the Promise 85
Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals? 84
Asthma, allergy and the olympics: A 12-year survey in elite athletes 82
Transparency and the European medicines agency - Sharing of clinical trial data 82
Innovative medicines: New regulatory procedures for the third millennium 81
First-in-human clinical trials - What we can learn from tragic failures 79
Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward 79
preventive peptide vaccine for colorectal cancer metastases 73
Drug regulation and pricing - Can regulators influence affordability? 72
Steps forward in regulatory pathways for acute and chronic heart failure 69
European regulatory experience with drugs for central nervous system disorders 68
The impact of parallel regulatory–health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations 64
Inhibitor of fatty acid amide hydrolase: learning from tragic failures [The editorialists reply] 52
Totale 30.104
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.603
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.603
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.391 0 0 0 0 0 0 0 0 0 0 731 660
2019/20207.802 699 620 567 687 589 788 663 643 609 577 681 679
2020/20215.532 639 721 643 643 493 693 673 477 156 145 201 48
2021/20221.057 33 123 55 30 27 97 85 41 99 72 62 333
2022/20231.250 137 54 45 135 100 314 103 85 89 12 149 27
2023/2024266 47 10 31 18 35 71 11 11 4 18 10 0
Totale 30.475